Follow
Małgorzata Bajor
Małgorzata Bajor
Mossakowski Medical Research Institute
Verified email at imdik.pan.pl
Title
Cited by
Cited by
Year
Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer
K Marhelava, Z Pilch, M Bajor, A Graczyk-Jarzynka, R Zagozdzon
Cancers 11 (11), 1756, 2019
782019
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen ReceptorsIntrinsic Functionality of NK Cells Affects CAR Retargeting
VYS Oei, M Siernicka, A Graczyk-Jarzynka, HJ Hoel, W Yang, D Palacios, ...
Cancer immunology research 6 (4), 467-480, 2018
652018
Maintenance of long‐term potentiation in hippocampal mossy fiber—CA3 pathway requires fine‐tuned MMP‐9 proteolytic activity
G Wiera, G Wozniak, M Bajor, L Kaczmarek, JW Mozrzymas
Hippocampus 23 (6), 529-543, 2013
572013
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer
PC O’Leary, M Terrile, M Bajor, P Gaj, BT Hennessy, GB Mills, ...
Breast Cancer Research 16 (4), 1-15, 2014
522014
Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma
A Trzeciecka, S Klossowski, M Bajor, R Zagozdzon, P Gaj, A Muchowicz, ...
Oncotarget 7 (2), 1717, 2016
442016
Synaptic cell adhesion molecule‐2 and collapsin response mediator protein‐2 are novel members of the matrix metalloproteinase‐9 degradome
M Bajor, P Michaluk, P Gulyassy, AK Kekesi, G Juhasz, L Kaczmarek
Journal of neurochemistry 122 (4), 775-788, 2012
412012
Proteolytic remodeling of the synaptic cell adhesion molecules (CAMs) by metzincins in synaptic plasticity
M Bajor, L Kaczmarek
Neurochemical research 38 (6), 1113-1121, 2013
402013
Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents
M Bajor, AO Zych, A Graczyk-Jarzynka, A Muchowicz, M Firczuk, ...
British journal of cancer 119 (7), 873-884, 2018
332018
Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate
A Graczyk-Jarzynka, A Goral, A Muchowicz, R Zagozdzon, M Winiarska, ...
Redox biology 21, 101062, 2019
262019
Complement components, proteolysis‑related, and cell communication‑related proteins detected in urine proteomics are associated with IgA nephropathy.
K Mucha, M Bakun, R Jazwiec, M Dadlez, M Florczak, M Bajor, K Gala, ...
Polish archives of internal medicine 124 (7-8), 380-38, 2014
242014
Adenanthin, a new inhibitor of thiol‐dependent antioxidant enzymes, impairs the effector functions of human natural killer cells
M Siernicka, M Winiarska, M Bajor, M Firczuk, A Muchowicz, M Bobrowicz, ...
Immunology 146 (1), 173-183, 2015
222015
Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy
M Firczuk, M Bajor, A Graczyk-Jarzynka, K Fidyt, A Goral, R Zagozdzon
Cancer letters 471, 1-11, 2020
212020
Application of genome editing techniques in immunology
AO Zych, M Bajor, R Zagozdzon
Archivum Immunologiae et Therapiae Experimentalis 66 (4), 289-298, 2018
202018
An interplay of S-nitrosylation and metal ion binding for astrocytic S100B protein
M Bajor, M Zaręba-Kozioł, L Zhukova, K Goryca, J Poznański, ...
PloS one 11 (5), e0154822, 2016
142016
The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance
K Retecki, M Seweryn, A Graczyk-Jarzynka, M Bajor
Cancers 13 (23), 6012, 2021
122021
Triple combination of ascorbate, menadione and the inhibition of peroxiredoxin-1 produces synergistic cytotoxic effects in triple-negative breast cancer cells
M Bajor, A Graczyk-Jarzynka, K Marhelava, M Kurkowiak, A Rahman, ...
Antioxidants 9 (4), 320, 2020
112020
PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress
M Klopotowska, M Bajor, A Graczyk-Jarzynka, A Kraft, Z Pilch, A Zhylko, ...
Cancer Immunology Research, 2021
92021
Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells
J Chlebowska-Tuz, O Sokolowska, P Gaj, M Lazniewski, M Firczuk, ...
haematologica 103 (11), 1843, 2018
92018
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
M Bajor, A Graczyk-Jarzynka, K Marhelava, A Burdzinska, A Muchowicz, ...
Journal for immunotherapy of cancer 10 (1), 2022
52022
Adenanthin, a new peroxiredoxin inhibitor, induces a switch between estrogen receptor alpha-mediated and Src/Akt-driven signaling in breast cancer cells
M Bajor, AO Zych, PC O'Leary, A Czekalska, WM Gallagher, J Golab, ...
CANCER RESEARCH 75, 2015
22015
The system can't perform the operation now. Try again later.
Articles 1–20